Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 1.69
NYMX's Cash-to-Debt is ranked lower than
75% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NYMX: 1.69 )
Ranked among companies with meaningful Cash-to-Debt only.
NYMX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 22.26 Max: No Debt
Current: 1.69
Equity-to-Asset -0.69
NYMX's Equity-to-Asset is ranked lower than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NYMX: -0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
NYMX' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.82  Med: 0.26 Max: 1
Current: -0.69
-7.82
1
Piotroski F-Score: 6
Altman Z-Score: -90.83
Beneish M-Score: -24.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3864.06
NYMX's Operating Margin % is ranked lower than
88% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NYMX: -3864.06 )
Ranked among companies with meaningful Operating Margin % only.
NYMX' s Operating Margin % Range Over the Past 10 Years
Min: -4531.34  Med: -790.51 Max: -145.43
Current: -3864.06
-4531.34
-145.43
Net Margin % -3936.88
NYMX's Net Margin % is ranked lower than
89% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NYMX: -3936.88 )
Ranked among companies with meaningful Net Margin % only.
NYMX' s Net Margin % Range Over the Past 10 Years
Min: -4616.2  Med: -796.99 Max: -146.14
Current: -3936.88
-4616.2
-146.14
ROA % -920.10
NYMX's ROA % is ranked lower than
99% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NYMX: -920.10 )
Ranked among companies with meaningful ROA % only.
NYMX' s ROA % Range Over the Past 10 Years
Min: -1676.25  Med: -274.32 Max: -89.58
Current: -920.1
-1676.25
-89.58
ROC (Joel Greenblatt) % -693722.22
NYMX's ROC (Joel Greenblatt) % is ranked lower than
100% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NYMX: -693722.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYMX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -693722.22  Med: -41488.76 Max: -22080.95
Current: -693722.22
-693722.22
-22080.95
3-Year Revenue Growth Rate -60.60
NYMX's 3-Year Revenue Growth Rate is ranked lower than
87% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NYMX: -60.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYMX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -60.6  Med: 4.9 Max: 91.3
Current: -60.6
-60.6
91.3
3-Year EBITDA Growth Rate 25.30
NYMX's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NYMX: 25.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYMX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -23.6  Med: 0.2 Max: 27.8
Current: 25.3
-23.6
27.8
3-Year EPS without NRI Growth Rate 26.00
NYMX's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NYMX: 26.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYMX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.3  Med: 0 Max: 27.8
Current: 26
-24.3
27.8
GuruFocus has detected 3 Warning Signs with Nymox Pharmaceutical Corp $NYMX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYMX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NYMX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2835
Compare: » details
Traded in other countries:NYM.Germany,
Headquarter Location:Bahamas
Nymox Pharmaceutical Corp, along with its subsidiaries, is a biopharmaceutical corporation, engaged in research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease.

Nymox Pharmaceutical Corp was incorporated under the Canada Business Corporations Act in May 1995. The Company is a biopharmaceutical corporation engaged in research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease. It has three proprietary products on the market, and a significant R&D pipeline of products in development for the treatment of such conditions and diseases as BPH, prostate cancer, Alzheimer's disease or AD, E. coli O157; H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company also has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's products include: NicAlert, TobacAlert and AlzheimAlert. The Company has developed and markets NicAlert and TobacAlert, test strips for determining whether a person is using tobacco products or has been recently exposed to second-hand smoke. It has also developed AlzheimAlert, a proprietary urine assay that can aid physicians in the diagnosis of Alzheimer's disease. The Company is also developing NX-1207, treatments for BPH and prostate and liver cancer. It is also developing NXC-4720, novel antibacterial agents for the treatment of E. coli O157 bacterial contamination in meat and other food and drink products. Its AlzheimAlert test is certified with a CE Mark, making the device eligible for sale in the European Union. The Company's competitors include: Eli Lilly and Company, GE Healthcare, Athena Diagnostics, Inc., Fujirebio Europe NV, Amorfix Life Sciences Ltd, LabCorp, Quest Diagnostics, OraSure Technologies Inc., Abraxis LLC, Roche Diagnostics, Abbott and Diagnostic Products Corporation.

Ratios

vs
industry
vs
history
PS Ratio 568.58
NYMX's PS Ratio is ranked lower than
95% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. NYMX: 568.58 )
Ranked among companies with meaningful PS Ratio only.
NYMX' s PS Ratio Range Over the Past 10 Years
Min: 3.98  Med: 209.33 Max: 672.86
Current: 568.58
3.98
672.86
EV-to-EBIT -16.03
NYMX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. NYMX: -16.03 )
Ranked among companies with meaningful EV-to-EBIT only.
NYMX' s EV-to-EBIT Range Over the Past 10 Years
Min: -161.8  Med: -26.4 Max: -2.7
Current: -16.03
-161.8
-2.7
EV-to-EBITDA -16.03
NYMX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. NYMX: -16.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
NYMX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -164.2  Med: -27.3 Max: -2.7
Current: -16.03
-164.2
-2.7
Current Ratio 0.88
NYMX's Current Ratio is ranked lower than
90% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. NYMX: 0.88 )
Ranked among companies with meaningful Current Ratio only.
NYMX' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.62 Max: 42.02
Current: 0.88
0.12
42.02
Quick Ratio 0.88
NYMX's Quick Ratio is ranked lower than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. NYMX: 0.88 )
Ranked among companies with meaningful Quick Ratio only.
NYMX' s Quick Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.59 Max: 42.02
Current: 0.88
0.09
42.02
Days Inventory 25.79
NYMX's Days Inventory is ranked higher than
85% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. NYMX: 25.79 )
Ranked among companies with meaningful Days Inventory only.
NYMX' s Days Inventory Range Over the Past 10 Years
Min: 25.79  Med: 46.01 Max: 143.72
Current: 25.79
25.79
143.72
Days Sales Outstanding 17.11
NYMX's Days Sales Outstanding is ranked higher than
85% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. NYMX: 17.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
NYMX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.13  Med: 6.76 Max: 57.91
Current: 17.11
0.13
57.91
Days Payable 2.00
NYMX's Days Payable is ranked lower than
91% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. NYMX: 2.00 )
Ranked among companies with meaningful Days Payable only.
NYMX' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 1927.71 Max: 4197.5
Current: 2
2
4197.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.30
NYMX's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NYMX: -12.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NYMX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.3  Med: -4.5 Max: -2.1
Current: -12.3
-12.3
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 2.71
NYMX's Price-to-Median-PS-Value is ranked lower than
90% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NYMX: 2.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NYMX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.05 Max: 2.92
Current: 2.71
0.02
2.92
Earnings Yield (Greenblatt) % -6.24
NYMX's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. NYMX: -6.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NYMX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -37.7  Med: -3.8 Max: -0.6
Current: -6.24
-37.7
-0.6

More Statistics

Revenue (TTM) (Mil) $0.32
EPS (TTM) $ -0.26
Beta1.39
Short Percentage of Float8.77%
52-Week Range $1.62 - 5.79
Shares Outstanding (Mil)50.45
» More Articles for NYMX

Headlines

Articles On GuruFocus.com
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT May 10 2017 
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference W May 08 2017 
NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe May 03 2017 
NYMOX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and K Jan 23 2015 
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceut Dec 02 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Nymox Pharmaceutical Dec 01 2014 

More From Other Websites
ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017 Jul 04 2017
Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH... May 31 2017
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
Nymox reports 1Q loss May 16 2017
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT May 10 2017
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference... May 08 2017
NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe May 03 2017
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017 Apr 05 2017
Pacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments Mar 30 2017
Company News for October 12, 2016 Oct 12 2016
Nymox Wins Big on Late-Stage Trial Oct 11 2016
Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype Aug 26 2016
Nymox Pharmaceutical Corporation (NYMX) Has More Upside Potential, Even After Gains Aug 25 2016
Why Nymox Pharma (NYMX) Closed the Day Up 83% Aug 24 2016
Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success Aug 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}